Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis
作者: Charles A. FieldBrittney H. CottaJuan JimenezBrian R. LaneKendrick YimHak J. LeeStephen T. RyanZachary A. HamiltonSunil PatelSong WangChristopher J. KaneSumi DeyRana R. MckaySabrina NoyesFrederick E. MillardBrian I. RiniSteven C. CampbellIthaar H. Derweesh
作者单位: 1UC San Diego School of Medicine, La Jolla, CA
2Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH
3Spectrum Health, Grand Rapids, MI
刊名: Clinical Genitourinary Cancer, 2019, Vol.17 (3), pp.e505-e512
来源数据库: Elsevier Journal
DOI: 10.1016/j.clgc.2019.01.013
关键词: Inferior vena cavaNeoadjuvant therapyNephrectomyRenal cell carcinomaSurvival
原始语种摘要: Abstract(#br)Background(#br)We analyzed outcomes of neoadjuvant sunitinib in patients with renal-cell carcinoma (RCC) and inferior vena caval (IVC) tumor and compared outcomes to patients who did not undergo neoadjuvant therapy before surgery.(#br)Patients and Methods(#br)We performed a multicenter retrospective comparison of RCC patients with IVC tumor who underwent neoadjuvant sunitinib before surgery versus those who did not. Response to sunitinib was defined by Response Evaluation Criteria in Solid Tumors (RECIST). Primary outcome was cancer-specific survival. Secondary outcomes included overall survival. Multivariate analysis was performed to identify risk factors associated with primary and secondary outcomes. Kaplan-Meier analysis compared survival in neoadjuvant and primary...
全文获取路径: Elsevier  (合作)
影响因子:1.429 (2012)

  • Analysis 分析